Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TLR4 | O00206 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5354872 | 1.00 | DRD4 (0.36) | DRD4RAB9AGAAALDH1A1LMNA | |
| SCHEMBL5455414 | 0.85 | GSK3B (0.33) | RAB9AGAAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL5455411 | 0.85 | GSK3B (0.33) | RAB9AGAAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL5215255 | 0.84 | GPBAR1 (0.36) | RAB9AGAAALDH1A1LMNAGRIN2B | |
| SCHEMBL5215249 | 0.84 | GPBAR1 (0.36) | RAB9AGAAALDH1A1LMNAGRIN2B | |
| SCHEMBL5351152 | 0.82 | SMN1; SMN2 (0.56) | GAAALDH1A1LMNANFE2L2KDM4E | |
| SCHEMBL5351150 | 0.82 | SMN1; SMN2 (0.56) | GAAALDH1A1LMNANFE2L2KDM4E | |
| SCHEMBL5349959 | 0.79 | RAB9A (0.59) | RAB9AGAAALDH1A1LMNANFE2L2 | |
| SCHEMBL5452893 | 0.78 | NOTUM (0.31) | — | |
| SCHEMBL5452890 | 0.78 | NOTUM (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | BOYD F LESLIE | 2007-12-13 | — | — | US | disclosed |
| US-7163940-B2 | Pyrazolopyridinyl pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-16 | — | — | US | disclosed |
| US-7160897-B2 | Therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-7109209-B2 | Pyrazolopyridines, process for their preparation and use as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| US-7087618-B2 | Pyrazolopyridinyl pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-08 | — | — | US | disclosed |
| US-7034030-B2 | Pyralopyridines, process for their preparation and use as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-20060058319-A1 | Pyrazolopyridines, process for their preparation and use as therapeutic compounds | ALBERTI MICHAEL J | 2006-03-16 | — | — | US | disclosed |
| US-20050182080-A1 | Therapeutic compounds | CHAMBERLAIN STANLEY D (US) | 2005-08-18 | — | — | US | disclosed |
| EP-1341788-B1 | PYRAZOLOPYRIDINES | GLAXO GROUP LTD (GB) | 2005-08-10 | — | — | EP | disclosed |
| US-20050171133-A1 | Therapeutic compounds | CHAMBERLAIN STANLEY D (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050049259-A1 | Theraopeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-03-03 | — | — | US | disclosed |
| US-20040072853-A1 | Therapeutic compounds | CHAMBERLAIN STANLEY D (US) | 2004-04-15 | — | — | US | disclosed |
| EP-1377573-A2 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-01-07 | — | — | EP | disclosed |
| EP-1372643-A1 | PYRAZOLOPYRIDINES, PROCESS FOR THEIR PREPARATION AND USE AS THERAPEUTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-01-02 | — | — | EP | disclosed |
| EP-1372642-A1 | USE OF PYRAZOLOPYRIDINES AS THERAPEUTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2004-01-02 | — | — | EP | disclosed |
| EP-1341788-A2 | PYRAZOLOPYRIDINES | GLAXO GROUP LIMITED (GB) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002078700-A1 | PYRALOPYRIDINES, PROCESS FOR THEIR PREPARATION AND USE AS THERAPTEUTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002078701-A1 | USE OF PYRAZOLOPYRIDINES AS THERAPEUTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002048147-A2 | PYRAZOLOPYRIDINES | GLAXO GROUP LIMITED (GB) | 2002-06-20 | — | — | WO | disclosed |
| WO-2002048148-A2 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049259-A1 | Theraopeutic compounds | PCSK9, FOLH1, EPHA2 | DRD4 4575/4885RAB9A 2333/4885GAA 74/4885 |
| US-20060058319-A1 | Pyrazolopyridines, process for their preparation and use as therapeutic compounds | CYP3A5, CYP3A4, CYP3A7 | DRD4 1059/4885RAB9A 1295/4885GAA 769/4885 |
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | CYP3A5, CYP2C19, CYP3A4 | DRD4 2270/4885RAB9A 1326/4885GAA 1465/4885 |
| US-20040072853-A1 | Therapeutic compounds | PCSK9, ABCB1, FURIN | DRD4 2179/4885RAB9A 1306/4885GAA 63/4885 |
| US-20050182080-A1 | Therapeutic compounds | PCSK9, FURIN, CYP11B2 | DRD4 2118/4885RAB9A 1444/4885GAA 62/4885 |
| US-20050171133-A1 | Therapeutic compounds | PCSK9, FURIN, CYP11B2 | DRD4 2118/4885RAB9A 1444/4885GAA 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.